DEPArray™ 單細胞分離篩選系統

DEPArray™系統平台可以分離出單顆完整的細胞,可針對稀少細胞的生物特徵進行研究,有助於癌症研究,治療反應偵測,藥物測試,胎兒生物,幹細胞等方面。市面上唯一自動化設備,可以辨識,量化,捕獲單顆稀少細胞DEPArray™系統包括特殊晶片和分析平台。

Menarini Silicon Biosystems

DEPArray™ 技術平台

DEPArray™技術原理

  • 介電場主動移動細胞。
  • DEPArray 系統包括特殊晶片和分析平台,是市面上唯一自動化設備,可以辨識,量化,捕獲單顆稀少細胞(Single rare cell)。

特殊晶片

利用DEPArray™技術來控制細胞的操縱和收集,單次使用。主要晶片區中~40,000個電極矩陣排列,當電極活化,不均勻電場形成電籠,包裹細胞懸浮。比利用電能移動原理,稱為介電電泳( DEP),能輕柔的將細胞移動到指定的位置上,可應用到細胞 間交互作用的研究,或是指定細胞分離和捕獲。

分析平台

使用高品質影像系統篩選,使目標細胞可以精確的分離。此自動化系統最多可配備5個螢光通道和一個可見光, 搭配CCD影像感應器, 可確認細胞螢光強度和形態上的特徵。該系統提供10倍放大率( 0.64微米/像素)和20倍放大率( 0.32微米/像素),使用CellBrowser™軟體操作,介面人性化,提供多參數篩選權限與各種分析圖表。可分離出1/1000~100比例的目標細胞,可應用在活細胞,死細胞,富集過後的細胞,針尖吸取液或組織切片等。

系統優勢

DEPArray™系統平台可以分離出單顆完整的細胞(Single cell),可針對稀少細胞(Rare cell)的生物特徵進行研究,有助於癌症研究,治療反應偵測,藥物測試,胎兒生物(NIPT),幹細胞等方面。

Pure。純淨

結合影像系統和微流體技術,可避免污染、細胞碎片或偽陽性細胞影響實驗,還可在同一個樣品中,同時進行正向和負向篩選。

Single。單顆

DEPArray™技術平台可使單顆細胞精準分離,有助於後續精確的分子分析。

Viable。存活

以溫和的方式捕獲細胞,使分離出的細胞可以直接垮養,存活率高。

實驗流程

DEPArray cartridge workflow

  1. 將細胞懸浮液注入晶片,掃描後存取細胞影像。
  2. 選取目標細胞,移動到暫存區。
  3. 將細胞依照實驗設計分離出來。

DEPArray™ 軟體介面

Cell Browser™

功能強大,直覺化操作

提供使用者最大的自由度來定義選擇標準,以影像為基礎做最精確的篩選。 DEPArray™系統中的Cell Browser™軟體根據影像基礎,篩選且捕獲樣品中的目標細胞和細胞族群。根據使用者的需求選擇螢光通道種類與明視野影像,對於任何以螢光標定的稀少細胞(Rare cell),有最大的靈活度設定分選條件。

Cell Browser™主要特性

  1. 自動收集數值:例如:峰值,螢光平均強度,細胞圓度,細胞直徑等。
  2. 多參數設定:可根據使用者的需求設定篩選條件,參數之間可設定交集或聯集,同時正向篩選及負向篩選。
  3. 多重顯示模式:點狀圖,直方圖和表格。
  4. 簡單地調整閥值

每一個細胞在介面中的影像欄位中,皆有各個螢光與可見光的獨立影像,也可自由選擇影像疊圖。每一個細胞擁有獨立編號,在列表中完整顯示此細胞的各項數值,例如:細胞周長,直徑,圓度,螢光強度等等。系統也允許同一個樣品中選取不同亞群,分別收集。並由影像確保分離的細胞是完整且單顆,取得純淨細胞進行後續精準的分析。

Cell Browser™操作介面:

DEPArray software interface

點狀圖方便使用者界定篩選範圈,X軸和Y軸的參數皆可自由更換。

DEPArray software select cells

可在同一個樣品中分出不同族群,並用不同顏色標示,圈中綠色點表示為CTC,藍色點是CTC的片段,紅色標示的為白血球(WBC)。一個點表示一個細胞,點還任何一個點,就會在下方影像列中出現此細胞的所有影像。

DEPArray software grid

In grid參數,可測量物件的中心和電極中心的距離。計算出在電極內的比例,用以自動移除有其他非目標細胞的汙染。

DEPArray software circularity

Circularity參數,用來評估物件的圓形度,以百分比顯示。可以分辨出原型的細胞和被拉長的細胞。


DEPArray™ 應用範圍

DEPArray™應用方向

適用多種研究領域及轉譯醫學的發展

癌症研究(Onecology research) 可由多樣化的檢體(組織、血液、FFPE 、細胞)分離出目標細胞,稀少的循環性腫瘤細胞(CTCs)亦可精確捕獲,分析腫瘤樣品中的異質性。

幹細胞研究(Stem cell reasearch) 分離臨床檢體中具有活性的幹細胞或癌幹細胞繼續培養,亦可根據幹細胞表面蛋白表達程度不同而分群分選。

胎兒細胞生物學(Fetal Cell Biology) 藉由分離母血中稀少的胎兒有核紅細胞進行基因檢測,可為非侵入性產檢開創新的運用。

免疫學(lmmunolgy) 利用功能性的的磁珠與目標細胞結合,可判斷細胞的表型而進一步分離目標細胞。

細胞間交互作用(Cell-cell interaction) 可指定細胞主動接觸,觀察毒殺細胞所引發的細胞裂解機制。

藥物測試 可於晶片中觀察記錄微脂體包覆小量化合物或奈米粒子進入細胞後的效果。

DEPArray™ 適用樣品種類

多重樣品皆可上機

疾病發展機制或抗藥性的發展,往往需要從不同類型的樣品中取得細胞來研究和比較特徵。DEPArray™系統平台可分離並捕獲樣品中稀少且純淨的目標細胞,不論是活細胞,死細胞或是螢光標定的細胞。

組織檢體 體液/血液 細胞樣品
  • Solid tissue biopsy
  • FFPE
  • Frozen tissue
  • Fine Needle Aspirates
  • Whole blood
  • Pleural fluid
  • Urine
  • Bone Marrow
  • Cell lines
  • IPSCs

DEPArray™可搭配多種後續分子分析

下游分析方式靈活

異質性的生物樣本中,重要的分子特徵會掩蓋在背景值中,無法從下游分析中得到結果。同樣的,汙染物、細胞碎片及偽陽性也會誤導結果,浪費資源。DEPArray™平台可分離出完整且純淨的細胞,連最具挑戰性的單細胞分析皆可應用,例如:WGA、Array CGH、NGS、Mutation和CNV分析,表達分析。

  • Whole genome amplifition (WGA) 全基因組擴增
  • Comparative genomic hybridization (CGH) 比較基因組雜交
  • Whole genome sequencing (WGS) 全基因組定序
  • Next generation sequencing (NGS) 次世代定序
  • Copy number variation analysis (CNV) 拷貝數變異分析
  • Mutation & Expression analysis 突變&表達分析
  • Microsatellite analysis 微衛星分析
  • Sanger Sequencing 桑格核酸定序

DEPArray™實際應用-腫瘤

DEPArray app cancer nm logo

Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer (2014)

DEPArray app cancer CarolineDive

Professor Caroline Dive,

Manchester Cancer Research Centre {MCRC}, winner of the 2012 Pasteur-Weizmann/Servier Prize

DEPArray app cancer UniOfManchester Logo

DEPArray app cancer Cancer Research UK logo

研究者介紹

Prof. Caroline Dive 是英國曼徹斯特大學藥理學教授,也是曼徹斯特癌症研究中心的傑出研究員(Manchester Cancer Research Centre),她與她的研究團隊致力於以非侵入性的方式,透過偵測血液中的循環性腫瘤細胞(Circulating tumor cells),歸納出可以實際應用於疾病診斷以及追蹤治療效果的資料庫,達到轉譯醫學的目的。

得獎介紹

The Pasteur-Weizmann/Servier為國際獎項,每三年會選出在生物藥品研發有傑出貢獻的料學家、研究員或醫師,這些傑出研究者在生藥領域的發現,提供病患更多有效的治療方法。PasteurWeizmann委員會和Servier研究機構主要的宗旨在於促進和鼓勵基礎研究的發展,尤其是將實驗室的成果,成功轉入臨床研究當中的傑出國隊。

實驗設計

DEPArray app cancer experiment design

論文摘要

小細胞肺癌(SCLC)在肺癌中佔15~20%,早期就轉移,預後差,多數病人無法以手術方式去除腫瘤。 Prof. Caroline Dive將病人周邊血液中的循環性腫瘤細胞(CTC)分離出來,成功在免疫不全的老鼠建立疾病模式(CTC-derived explants, CDXs),與病人相似,可藉由動物模式測試藥物,選取最適合藥物進行治療,邁向個人化醫療。文中並比較CTC與CDXs站在基因表現上高度相關, CTC有益於監控病程,CDXs有助於研究抗藥性的作用機制。


DEPArray™實際應用-幹細胞

分離人類脂肪幹細胞(hADSCs)可繼續培養

DEPArray app stem hADSCs isolation with 50ml tubes
由美容手術中的脂肪組織,取得脂肪幹細胞。
DEPArray app stem hADSCs isolation with cell culture flasks
以膠原蛋白酶將細胞單顆化並培養與擴增,多數貼附的細胞(@ P2-P3)是間質幹細胞且參雜內皮細胞(endothelial cells)、單核球(monocytes)與纖維母細胞 (fibroblast)。
DEPArray app stem hADSCs isolation with cartridge
細胞以染CD45做為負標記,並使用DEPArray去識別,回收沒有標記的人類脂肪幹細胞(hDSCs)。
DEPArray app stem hADSCs isolation with DEPArray
Multiple recoveries of CD45 neg cells were plated to micro dishes for proliferation 8 x 1 cell 2 x 10 cells 1×100 cells
  • 63%的單顆人類脂肪幹細胞克隆存活(5/8)
  • 回收的多顆細胞(2 x 10 cells & 1 x 100 cells )全數存活

分離人類脂肪幹細胞(hADSCs)培養後可正常誘導分化

DEPArray app stem hADSCs isolation figure 01

DEPArray app stem hADSCs isolation figure 02

DEPArray app stem hADSCs isolation figure 03

分選出UEA-1不同程度表現的hPSCs 進行後續分子分析

DEPArray app stem hADSCs isolation figure 04

World Stem Cell Summit 2013 / Poster Submission ID: 34191 Dissecting Molecular Heterogeneity in Pluripotent Stem Cells with Single-cell resolution

將hPSCs以UEA-1標示,分選出不同程度表現的族群,分離出單細胞,進行RT-RCP 分析。 比較下列三組細胞中28個基因表現情況: (1)UEA-1表現量高的幹細胞 (2)UEA-1表現量低的幹細胞 (3)已分化的神經前驅細胞(NPCs) 可得知分化前的幹細胞和分化後有哪些基因消長,以揭開分化調控的機制。 (pluripotency-associated lectin – UEA-1)


DEPArray™實際應用-免疫

Cell-cell interaction

原理

以紅色螢光標示免疫細胞,以綠色螢光標示目標細胞,在DEPArray™系統中,以電場包裹單顆細胞並主動靠近,若是免疫細胞會毒殺目標細胞,則目標細胞的綠色螢光清滅。

DEPArray app immune cell-cell interaction principle

實驗

利用DEPArray™影像功能,可長時間觀察,看細胞螢光的消減速度,判斷出胞殺作用的效率及相關的接收器。有助於研究並比較CTLs 或NK cells 兩種細胞進行胞殺作用的詳細機制,進而找到毒殺腫瘤細胞的新方向。

DEPArray app immune cell-cell interaction experiment data


DEPArray™實際應用-藥測

Drug response

將目標細胞和有藥物附著的磁珠同時注入晶片中,都可以利用電場單顆獨立懸浮在晶片中,然後主動控制磁珠一顆顆與目標細胞接觸,藉由目標細胞的螢光清滅,可觀察藥物劑量與細胞毒殺的效果。

紅色箭頭:目標細胞(Target Cell) 黃色箭頭:有藥物的磁珠

DEPArray app drugs response

相關產品

持續優化的流程

CTC分析優化流程

CELLSEARCH® System
CTC檢測系統

目前唯一通過美國FDA認證的CTCs檢測技術,具有精準性與可重複性;在乳癌、大腸直腸癌與前列腺癌已有臨床檢驗標準,可做為評估指標。利用免疫磁珠與免疫螢光捕捉與標定CTCs,全程自動化,可降低人為影響。一次最多可以同時執行8個樣品,適合應用於定期監測病患狀況,評估藥物療效與復發跡象。於研究方面,也陸續開發不同類型細胞的試劑組,使研究人員能依據需求富集特殊細胞。

DEPArray™ NxT
單細胞分離篩選系統

隨著DEPArray™ 技術的發展,基因的異質性研究可達單顆細胞層級。可探索每顆細胞基因中隱藏的故事,例如整倍體的基因變異。DEPArray™ 技術可依細胞表型分選,以及運用不同參數組合與影像系統的雙重確認,可確保分選出純度100%的標的細胞,採用高純度細胞故可觀察出等位基因表現。

最新機型!時間更快、回收更多、體積更小!

Ampli1™ WGA Kit
單顆細胞全基因組擴增套組

單顆細胞中使全基因組擴增優化,單一引子進行PCR,確保相間比例擴增DNA片段,平均且完整擴增DNA片段,擴增長度0.2~2K bp 適用任何種類的細胞,單管操作,無需沉澱DNA,滅少損失,過程快速,手動操作時間1.5小時,單顆細胞最多可獲得4ug DNA 適用於後續的基因分析應用,包括全基因組定序。

Ampli1™ LowPass Kit
染色體非整倍體和拷貝數變異 建庫套組

接續Ampli1™ WGA Kit產物使用Ampli1™ LowPass Kit,可輕鬆完成測序前建庫,免除中間複雜的實驗流程,像是純化,去掉adaptor,再接合等步驟。

此產品目前沒有詳細的產品列表,請來電洽詢。

DEParray™ 在腫瘤學Oncology的應用

Cariati et al, Int Journal of Molecular Sciences 2019, “Dissecting Intra-Tumor Heterogeneity by the Analysis of Copy Number Variations in Single Cells: The Neuroblastoma Case Study

Meyer et al, Human Pathology 2019 “Co-expression of cytokeratin and vimentin in colorectal Cancer highlights a subset of tumor buds and an atypical Cancer-associated stroma

Hodara et al, Journal od Clinical Oncology Insights 2019, “Multi-parametric liquid biopsy analysis in metastatic prostate cancer

Dorssers et al, British Journal of Cancer 2019, “Molecular heterogeneity and early metastatic clone selection in testicular germ cell cancer development

Rihawi et al, Translational Oncology 2019, “Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report

Vishnoi et al, Cancer Research 2018, “Targeting USP7 Identifies a MetastasisCompetent State within Bone Marrow–Resident Melanoma CTCs

De Laere et al, Clinical Cancer Research 2018, “TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer

Chalopin et al, Journal of Bone Oncology, 2018 “Isolation of circulating tumor cells in a preclinical model of osteosarcoma: effect of chemotherapy

Petrossian et al, Oncotarget 2018, “ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer

Ji Won Lee et al, Journal of Applied Genetics 2018, “Identification of novel mutations in FFPE lung adenocarcinomas using DEPArray sorting technology and next-generation sequencing

Ferrarini A et al, PLOS ONE 2018, “A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products

Boulding et al, Scientific Reports 2018, “LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer

Paoletti et al, Cancer Research 2017, “Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms

Boral et al, Nature Communications 2017, “Molecular characterization of breast cancer CTCs associated with brain metastasis

Mesquita et al, Molecular Oncology 2017, “Molecular analysis of single circulating tumour cells following long-term storage of clinical samples

Paolillo et al, Clinical Cancer Research 2017, “Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells

Palmirotta et al, Cancer Genomics and Proteomics 2017, “Next-generation Sequencing (NGS) Analysis on Single Circulating Tumor Cells (CTCs) with No Need of Whole-genome Amplification (WGA)

Rapp C et al, Acta Neuropathol 2017, “Identification of T cell target antigens in glioblastoma stem‑like cells using an integrated proteomics‑based approach in patient specimens

Bingham C et al, Breast Cancer Res Treat 2017, “Mutational studies on single circulating tumor clles isolated form the blood of inflammatory breast cancer patients

Tellez Gabriel M et al, European Journal of Cell Biology 2017, “Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip

De Laere B et al, JTS 2016, “Patients with metastatic hormone receptor-positive breast cancer express PIK3CA oncogene mutational heterogeneity in circulating tumor cells

Carter L et al, Nature Medicine 2016, “Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemo sensitive and chemo refractory small-cell lung cancer

Zhaomei Mu et al, IJMC 2016, “Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer

Shaw J et al, Clinical Cancer Research 2016, “Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high CTC counts

Millner LM et al, Cancer Research Frontiers 2016, “Comprehensive isolation, identification, and nucleic acid analysis of single breast cancer cells: CTC-isoTECH

De Luca F et al, Oncotarget 2016, “Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer

Bulfoni M et al, Breast Cancer Research 2016, “In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis

Yee S.S et al, Molecular Genetics and Genomic Medicine 2016, “A novel approach for next-generation sequencing of circulating tumor cells

Bolognesi C et al, Nature Scientific Reports 2016, “Digital Sorting of Pure Cell Populations Enables Unambiguous Genetic Analysis of Heterogeneous Formalin-Fixed Paraffin-Embedded Tumors by Next Generation Sequencing

Rothwell G et al, Molecular Oncology 2015, “Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample

Vishnoi M et al, Nature Scientific Reports 2015, “The isolation and characterization of CTC subsets related to breast cancer dormancy

Salvianti et al, Biomolecular Detection and Quantification 2015, “Feasibility of a workflow for the molecular characterization of singlecells by next generation sequencing

Ewelina Krzywinska et al, EBioMedicine 2015, “Identification of Anti-tumor Cells Carrying Natural Killer (NK) Cell Antigens in Patients with Hematological Cancers

Maltoni R et al, Cancer Letters 2015, “Circulating tumor cells in early breast cancer: A connection with vascular invasion

Pestrin M et al, Molecular Oncology 2014, “Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients

Fernandez S.V. et al, Breast Cancer Research 2014, “TP53 mutations detected in circulating tumor cellspresent in the blood of metastatic triple negative breast cancer patients

Carpenter E, et al, Frontiers in Oncology 2014, “Dielectrophoretic capture and genetic analisys of single neuroblastoma tumor cells

Hodgkinson C.L.et al, Nature Medicine 2014, “Tumorigenicity and genetic profiling of Circulating Tumor Cells in Small Cell Lung Cancer

Peeters DJE, et al. British Journal of Cancer 2013, “Semiautomated isolation and molecular characterization of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting

Fabbri F, et al. Cancer Letters 2013, “Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs


DEParray™ 在法醫鑑識Forensic的應用

Anslinger et al, Rechtsmedizin 2019, “Deconvolution of blood-blood mixtures using DEPArrayTM separated single cell STR profiling

Anslinger K et al, International Journal of Legal Medicine 2018, “Whose blood is it? Application of DEPArray™ technology for the identification of individual/s who contributed blood to a mixed stain

Williamson VR et al, FSI Genetics 2018, “Enhanced DNA Mixture Deconvolution of Sexual Offense Samples Using the DEPArrayTM System

Aslinger K et al, Rechtsmedizin 2017, “Application of DEPArray™ technology for the isolation of white blood cells from cell mixtures in chimerism analysis

Fontana F et al, FSI Genetics 2017, “Isolation and genetic analysis of pure cells from forensic biological mixtures: The precision of a digital approach

Hansson O et al, FSI Genetics 2017, “Characterization of artefacts and drop-in events using STR-validator and single-cell analysis


DEParray™ 在蠟塊包埋FFPE的應用

Meyer et al, Human Pathology 2019 “Co-expression of cytokeratin and vimentin in colorectal Cancer highlights a subset of tumor buds and an atypical Cancer-associated stroma

Dorssers et al, British Journal of Cancer 2019, “Molecular heterogeneity and early metastatic clone selection in testicular germ cell cancer development

Isidori et al, BMC Cancer 2018, “Genomic profiles of primary and metastatic esophageal adenocarcinoma identified via digital sorting of pure cell populations: results from a case report

Ji Won Lee et al, Journal of Applied Genetics 2018, “Identification of novel mutations in FFPE lung adenocarcinomas using DEPArray sorting technology and next-generation sequencing

Bolognesi C et al, Nature Scientific Reports 2016, “Digital Sorting of Pure Cell Populations Enables Unambiguous Genetic Analysis of Heterogeneous Formalin-Fixed Paraffin-Embedded Tumors by Next Generation Sequencing


DEParray™ 在分離幹細胞Isolation of Stem Cells的應用

Silvestris et al, Human Reproduction 2018, “In vitro differentiation of human oocytelike cells from oogonial stem cells: single-cell isolation and molecular characterization


DEParray™ 在蠟塊包埋FFPE應用的社論

Kathy Liszewski, GEN 2016, “The Next Next Thing in Sequencing

Farideh Bischoff, Nicolò Manaresi and Chiara Bolognesi, GEN 2015, “Isolation of Pure Tumor Cell Populations


DEParray™技術出版品

以下參考文獻是有關於介電泳技術和移動細胞的原理

Abonnenc M et al, J Immunol 2013, “Lysis-on-Chip of Single Target Cells following Forced Interaction with CTLs or NK Cells on a Dielectrophoresis-Based Array

Abonnenc M et al, Anal. Chem. 2013, “Programmable Interactions of Functionalized Single Bioparticles in a Dielectrophoresis-Based Microarray Chip

Gagnon ZR, Electrophoresis 2011, “Cellular dielectrophoresis: applications to the characterization, manipulation, separation and patterning of cells

Fabbri E et al, J Appl Polymer Sci 2008, “Levitation and movement of tripalmitin-based cationic lipospheres on a dielectrophoresis-based lab-on-a-chip device

Borgatti M et al, Int J Mol Med 2008, “New trends in non-invasive prenatal diagnosis: Applications of dielectrophoresis-based Lab-on-a-chip platforms to the identification and manipulation of rare cells

Vulto P et al, J Micromech Microeng 2006, “Selective sample recovery of DEP-separated cells and particles by phaseguide-controlled laminar flow

Fuchs AB et al, Lab Chip 2005, “Electronic Sorting and Recovery of Single Live Cells From Microlitre Sized Samples

Borgatti M et al, Int J Mol Med 2005, “Separation of White Blood Cells From Erythrocytes on a Dielectrophoresis (DEP) Based ‘Lab-On-A-Chip’ Device

Borgatti M et al, International Journal Oncology 2005, “Dielectrophoresis-based ‘Lab-on-a-chip’ devices for programmable binding of microspheres to target cells

Abonnenc M et al, NanoBiotechnology 2005, “A dielectrophoretic microchip for controlled cell targeting with functionalized microspheres

Medoro G et al, IEEE Sensors J 2003, “A lab-on-a-chip for cell detection and manipulation

Altomare L et al, Biotechnol and Bioeng 2003, “Levitation and movement of human tumor cells using a printed circuit board device based on software-controlled dielectrophoresis

Gascoyne PR et al, Electrophoresis 2002, “Particle separation by dielectrophoresis

Archer S et al, Biochem Biophys Res Commun 1999, “Cell Reactions to Dielectrophoretic Manipulation

此產品目前沒有其他的檔案下載,請來電洽詢。

您可能也喜歡…

  • Ampli1 WGA Kit

    Ampli1™ WGA Kit 單顆細胞全基因組擴增套組

    Ampli1™ WGA Kit 單顆細胞全基因組擴增套組 ,單顆細胞中使全基因組擴增優化,單一引子進行PCR,確保相間比例擴增DNA片段,平均且完整擴增DNA片段,擴增長度0.2~2K bp 適用任何種類的細胞,單管操作,無需沉澱DNA,滅少損失,過程快速,手動操作時間1.5小時,單顆細胞最多可獲得4ug DNA 適用於後續的基因分析應用,包括全基因組定序。

    查看內容
  • Ampli1 WTA Kit

    Ampli1™ WTA Kit 單顆細胞全轉錄組擴增套組

    Ampli1™ WTA Kit 單顆細胞全轉錄組擴增套組,單顆細胞中使全轉錄組放大優化,平均且完整放大RNA片段,擴增長度200-10,000 bp,平均500~600bp,單管操作, 減少RNA損失,單顆細胞可獲得2.3~4ug cDNA,不需要Dnase或是RnaseH,單顆細胞可同時放大DNA&RNA。

    查看內容